Cost-Effective Approach to AAV Viral Vector Manufacturing - Due to its outstanding safety profile and effective transduction to diverse target tissues, adeno-associated virus, often known as AAV, has emerged as a major platform for the delivery of therapeutic genes for the treatment of a wide range of disorders. In contrast, the manufacturing of viral vectors at large scales and their long-term storage are inefficient processes, which leads to lower yields, middling purity, and a shorter shelf life as compared to those of recombinant protein treatments.
No takes yet. Share an insight, caveat, or question.
Alotaibi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: